Daiichi Sankyo Company, Limited

Ube Industries, Inc.

Katsuhiro Kobayashi

Masahiro Ota

Takeshi Jimbo

Takashi Suzuki

Koichi Nakamura

Noriyasu Haginoya

Yosuke Ando

Jun Watanabe

Hideaki Watanabe

Hiroyuki Naito

Toshio Kaneko

Masahiko Hagihara

Kentaro Ito

Tomoharu Tsukada

Miho Hayakawa

Hitoshi Ohki

Yoshihiro Shibata

Yoshiko Kagoshima

Yuichi Tominaga

Motohisa Shimizu

Ryutaro Kanada

Saito Higuchi

Daisuke Fukatsu

Akitake Yamaguchi

Keijiro Kobayashi

Hideaki Funami

Akifumi Nakamura

Akiko Egami

Masayoshi Asano

Kosuke Takeuchi

Makoto Haruta

Yasushi Yoshigae

The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: 

EP300/CREBBP inhibitor

The present disclosure provides novel compounds or salts thereof, or crystals of the compounds or the salts, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl. The present disclosure provides pyridone derivatives having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or salts thereof, or crystals of the compounds or the salts, wherein R, R, R, R, R, W, X, Y, and Z are each as defined in the specification: 

Pyridone derivatives having tetrahydropyranylmethyl groups

A crystal of a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein Ris a hydrogen atom or a hydroxy group, and R is a 2-(trifluoromethyl)pyrimidin-5-yl group or a 5-(trifluoromethyl)pyrazin-2-yl group.

Crystal of 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative

Novel compounds or salts thereof, or crystals thereof, which inhibit Axl and are useful for treating diseases caused by Axl hyperfunction, diseases associated with Axl hyperfunction and/or diseases accompanied by Axl hyperfunction are provided. Pyridone derivatives represented by the formula (1) having various substituents or salts thereof, or crystals thereof (where R, R, R, R, R, A, W, X and n in the formula (1) are as defined in the specification, respectively) are provided.

Pyridone derivatives

Growing community of inventors

Tokyo, Japan

Katsuhiro Kobayashi